Evaluation of the therapeutic index of a novel phosphodiesterase 4B - Selective inhibitor over phosphodiesterase 4D in mice

Journal of Pharmacological Sciences

Volumn 123, Issue 3, 2013, Pages 219-226

  Suzuki, Osamu ^a,b   Mizukami, Kiyoshi ^a   Etori, Maki ^a   Sogawa, Yoshitaka ^a   Takagi, Nana ^a   Tsuchida, Hiroshi ^a   Morimoto, Kiyoshi ^a   Goto, Taiji ^a   Yoshino, Toshiharu ^a   Mikkaichi, Tsuyoshi ^a   Hirahara, Kazuki ^a   Nakamura, Satoshi ^b   Maeda, Hiroaki ^a  

^a DAIICHI SANKYO CO   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Anti inflammatory effect; Gastric adverse effect; Phosphodiesterase 4B (PDE4B); Phosphodiesterase 4D (PDE4D); Therapeutic index

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPOUND A; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; LUNG DISEASE; MALE; MOUSE; NEUTROPHILIA; NONHUMAN; PROTEIN BLOOD LEVEL; PULMONARY NEUTROPHILIA; STOMACH EMPTYING;

ADMINISTRATION, OPHTHALMIC; AMINOPYRIDINES; ANIMALS; BENZAMIDES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; GASTRIC EMPTYING; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LEUKOCYTE DISORDERS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; NEUTROPHILS; PHENYLACETATES; PHOSPHODIESTERASE 4 INHIBITORS; PNEUMONIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890504458     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13103FP     Document Type: Article

References (23)

1. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998; 157:351-370.
2. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011;204:391-414.
3. Diamant Z, Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther. 2011;24:353-360.
4. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23:235-256.
5. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-175.
6. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110:1045-1052.
7. Jin SL, Ding SL, Lin SC. Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J. 2012;35:197-210.
8. Kranz M, Wall M, Evans B, Miah A, Ballantine S, Delves C, et al. Identification of PDE4B over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorg Med Chem. 2009;17:5336-5341.
9. Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T, et al. Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett. 2009;19:3174-3176.
10. Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2- hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004;310:752-760.
11. Petursdottir DH, Hardardottir I. Dietary fish oil increases the number of splenic macrophages secreting TNF-alpha and IL-10 but decreases the secretion of these cytokines by splenic T cells from mice. J Nutr. 2007;137:665-670.
12. Ma Z, Li J, Yang L, Mu Y, Xie W, Pitt B, et al. Inhibition of LPS- and CpG DNA-induced TNF-alpha response by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol. 2004;286:L808-L816.
13. Basit A, Reutershan J, Morris MA, Solga M, Rose CE Jr, Ley K. ICAM-1 and LFA-1 play critical roles in LPS-induced neutrophil recruitment into the alveolar space. Am J Physiol Lung Cell Mol Physiol. 2006;291:L200-L207.
14. Mine Y, Oku S, Yoshida N. Anti-emetic effect of mosapride citrate hydrate, a 5-HT4 receptor agonist, on selective serotonin reuptake inhibitors (SSRIs)-induced emesis in experimental animals. J Pharmacol Sci. 2013;121:58-66.
15. PrDAXAS™ (http://www.takedacanada.com/ ca/~/media/Countries/ca/Files/Product%20PDFs/ Daxas%20English%20Distribution%2031-May%202011-with%20logo.pdf)
16. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;28:7628-7633.
17. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol. 2005;175:1523-1531.
18. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux M, et al. Nonredundant function of phosphodiesterase 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol. 2004;173:7531-7538.
19. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax. 2004;59:837-842.
20. Cowburn AS, Condliffe AM, Farahi N, Summers C, Chilvers ER. Advances in neutrophil biology: clinical implications. Chest. 2008;134:606-612.
21. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65:930-936.
22. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926-934.
23. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126:926-934.